Conterno Enrique A
Chief Executive Officer at FGEN; SVP&Pres, LillyDiab & LillyUSA at LLY
- Sold, on record
- $14.8M
- Dollars the filings state
- Form 4 sales
- 24
- Latest Jul 7, 2023
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale LLYPlan not statedMay 31 2018
Sold 25,000 shares at $85.00 ($2.1M)
Conterno Enrique A, SVP&Pres, LillyDiab & LillyUSA
Sold 16.7% of holdings ($12.7M position)124,534 shares leftFiling
- 2 Form 4 sale LLYPlan not statedFeb 15 +260 days
Sold 25,000 shares at $121.00 ($3M)
Conterno Enrique A, SVP&Pres, LillyDiab & LillyUSA
Sold 15.8% of holdings ($19.1M position)132,962 shares leftFiling
- 3 Form 4 sale FGENPlan not statedDec 8 +1392 days
Sold 2,543 shares at $15.79 ($40k)
Conterno Enrique A, Chief Executive Officer
Sold 0.8% of holdings ($4.7M position)297,020 shares leftFirst sale on recordFiling
- 4 Form 4 sale FGENPlan not statedJan 6 +29 days
Sold 1,538 shares at $19.95 ($31k)
Conterno Enrique A, Chief Executive Officer
Sold 0.5% of holdings ($5.9M position)295,483 shares leftFiling
- 5 Form 4 sale FGENPlan not statedMar 10 +63 days
Sold 56,261 shares at $20.62 ($1.2M)
Conterno Enrique A, Chief Executive Officer
Sold 12.8% of holdings ($9.1M position)384,868 shares leftFiling
- 6 Form 4 sale FGENNo planApr 10 +31 days
Sold 1,869 shares at $19.52 ($36k)
Conterno Enrique A, Chief Executive Officer
No 10b5-1 planSold 0.5% of holdings ($7.5M position)382,999 shares left0.7x usual sizeFiling
- 7 Form 4 sale FGENUnusualJun 7 +58 days
Sold 8,897 shares at $17.04 ($152k)
Conterno Enrique A, Chief Executive Officer
No 10b5-1 planSold 2.3% of holdings ($6.6M position)376,602 shares left4x usual sizeFiling
- 8 Form 4 sale FGENNo planJul 7 +30 days
Sold 1,880 shares at $2.80 ($5k)
Conterno Enrique A, Chief Executive Officer
No 10b5-1 planSold 0.5% of holdings ($1.1M position)374,722 shares left0.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (24)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2023 | FGEN | Chief Executive Officer | Form 4 sale | 1,880 | $5k | 0.5% | No plan | SEC |
| Jun 7, 2023 | FGEN | Chief Executive Officer | Form 4 sale | 8,897 | $152k | 2.3% | Unusual | SEC |
| Apr 10, 2023 | FGEN | Chief Executive Officer | Form 4 sale | 1,869 | $36k | 0.5% | No plan | SEC |
| Mar 10, 2023 | FGEN | Chief Executive Officer | Form 4 sale | 56,261 | $1.2M | 12.8% | Plan not stated | SEC |
| Jan 6, 2023 | FGEN | Chief Executive Officer | Form 4 sale | 1,538 | $31k | 0.5% | Plan not stated | SEC |
| Dec 8, 2022 | FGEN | Chief Executive Officer | Form 4 sale | 2,543 | $40k | 0.8% | Plan not stated | SEC |
| Feb 15, 2019 | LLY | SVP&Pres, LillyDiab & LillyUSA | Form 4 sale | 25,000 | $3M | 15.8% | Plan not stated | SEC |
| May 31, 2018 | LLY | SVP&Pres, LillyDiab & LillyUSA | Form 4 sale | 25,000 | $2.1M | 16.7% | Plan not stated | SEC |
| May 4, 2017 | LLY | SVP&Pres, LillyDiab & LillyUSA | Form 4 sale | 25,000 | $2.1M | 18.0% | Plan not stated | SEC |
| Dec 9, 2015 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 25,000 | $2.1M | 22.1% | Unusual | SEC |
| Nov 3, 2014 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $330k | 6.4% | Plan not stated | SEC |
| Oct 1, 2014 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $324k | 6.0% | Plan not stated | SEC |
| Sep 2, 2014 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $318k | 5.7% | Plan not stated | SEC |
| Jul 25, 2014 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 10,000 | $638k | 10.2% | Plan not stated | SEC |
| Aug 15, 2013 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $269k | 8.0% | Plan not stated | SEC |
| Jul 15, 2013 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $257k | 7.4% | Plan not stated | SEC |
| Jun 17, 2013 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $262k | 6.9% | Plan not stated | SEC |
| May 15, 2013 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $281k | 6.5% | Plan not stated | SEC |
| Apr 15, 2013 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $286k | 6.5% | Plan not stated | SEC |
| Aug 1, 2012 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $221k | 15.6% | Plan not stated | SEC |
| Jul 2, 2012 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $215k | 13.5% | Plan not stated | SEC |
| Jun 1, 2012 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $203k | 11.9% | Plan not stated | SEC |
| May 1, 2012 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $207k | 10.6% | Plan not stated | SEC |
| Apr 2, 2012 | LLY | Sr. VP & Pres., Lilly Diabetes | Form 4 sale | 5,000 | $202k | 9.6% | Plan not stated | SEC |